Malaria kills more children than previously estimated according to World Malaria Report Yet worst-case scenario predictions on the impact of COVID-19 on malaria control were averted 6 December 2021
MMV launches innovative drug research tool MMVSola aims to accelerate the selection of the best candidate drugs. 1 December 2021
MMV deeply saddened by the loss of Dr Martin de Smet Dedicated MSF malaria specialist and MMV APMAC co-chair will be sorely missed 1 December 2021
Dr Elizabeth Winzeler elected to the National Academy of Medicine MMV partner recognized for her pioneering malaria research 21 October 2021
First-ever malaria vaccine to get WHO recommendation for roll-out GSK’s RTS,S vaccine is an important complement to existing malaria interventions. 7 October 2021
First real-world use of new protocol for P. vivax case management in Brazil – a Health Ministry and MMV collaboration New treatment protocol can potentially change the way P. vivax malaria is managed. 7 October 2021
Novartis and Medicines for Malaria Venture report positive results for Phase IIb study of novel ganaplacide/lumefantrine combination in children with malaria 29 September 2021
New partnership launched to accelerate elimination of relapsing P. vivax malaria that poses a risk to an estimated 2.5 billion people worldwide Partnership to support endemic countries in achieving their Plasmodium vivax (P. vivax) malaria elimination goals. 14 July 2021
Pyronaridine-artesunate demonstrates high real-life safety, tolerability and effectiveness in the treatment of uncomplicated malaria in large multi-country study in Africa Study run in partnership with the CANTAM network and published in PLoS Medicine supports further uptake of antimalarial in Africa. 17 June 2021
MMV devises a predictive tool to assess resistance to antimalarial compounds and guide their development 31 May 2021
MMV and DNDi urge WHO member states to invest in medicines for women and children Statement delivered at 74th World Health Assembly. 27 May 2021
MMV and partners recognize malaria innovations and urge WHO member states to scale up investments Statement submitted to 74th World Health Assembly. 26 May 2021
MMV deeply saddened by the loss of Ambassador Dr Konji Sebati South African doctor, diplomat and MMV Board member will be sorely missed. 18 May 2021
MMV recognizes partner Novartis’ milestone of 1 billion courses of antimalarial delivered Milestone includes delivery of 430 million pediatric treatments since 1999. 18 May 2021
SMC scale-up significantly reduces child mortality in the Sahel MMV welcomes the critical body of evidence gathered on the considerable and positive impact of SMC at scale published in The Lancet. 10 May 2021
MMV’s partner S Kant receives WHO prequalification for its protective medicine for children Supyra® becomes the second seasonal malaria chemoprevention medicine to be prequalified. 23 April 2021
This World Malaria Day MMV recognizes Swiss Malaria Group's commitment to defeating malaria MMV echoes Swiss Malaria Group's recognition of progress made despite challenges posed by COVID-19, and supports the call for sustained commitment. 19 April 2021
MMV mourns the loss of Professor Sir Colin Dollery Pioneer in clinical pharmacology will be deeply missed 29 January 2021
New report demonstrates how R&D partnerships serving neglected communities have developed dozens of life-saving innovations since 2010 PDPs reduce investment risks and stretch limited budgets leading to 375 innovations targeting infectious diseases under development. 28 January 2021
Republic of Korea grants USD 10 million to MMV-led consortium to protect children from malaria in the Sahel SMC IMPACT aims to expand use of seasonal malaria chemoprevention in five African countries. 28 January 2021
GSK, MMV filing for Kozenis (tafenoquine) in paediatric populations with Plasmodium vivax malaria accepted by Australian Therapeutic Goods Administration Acceptance to review the paediatric dossier by the Australian drug regulator is an important and big step towards making this medicine available to the children that need it 8 January 2021
MMV awards Project of the Year 2020 to Professor David Fidock and team for critical contribution to malaria drug resistance profiling Team recognized for transformational impact on MMV’s resistance work over past decade, which is today supporting compound prioritization. 18 December 2020